SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...

Transcatheter mitral valve repair with the PASCAL device showed high rates of survival and freedom from heart failure rehospitalization at 2 years in the single-arm, safety and efficacy CLASP study.

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment ...

In patients with a poorly functioning bioprosthetic mitral valve in the heart, a minimally invasive procedure to insert a new valve was associated with a lower rate of death or disabling stroke within ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

TCT 748: Effects of SGLT2 Inhibitors on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus Undergoing Transcatheter Mitral Valve Repair: A Propensity-Matched Analysis ...

Patients who underwent mitral valve replacement had a more than threefold higher 10-year rate of infective endocarditis than those at moderate risk for the disease, whereas undergoing mitral valve ...